Herbs (Global Traditional) · Ayurveda
Eranda (Ricinus communis) (Ricinus communis)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Eranda (Ricinus communis) contains ricinoleic acid as its primary bioactive compound, which acts as an osmotic laxative by drawing water into the intestines. The castor oil derived from eranda seeds is FDA-approved for constipation relief and shows preliminary antibacterial properties.
Eranda (Ricinus communis), commonly known as castor bean plant, is a perennial flowering shrub native to Africa and cultivated globally in tropical regions for its seeds. Castor oil is extracted through cold-pressing or solvent extraction after purification to remove the toxic ricin, typically via fomentation in coconut water followed by washing and drying. The oil consists primarily of ricinoleic acid, a hydroxylated fatty acid comprising approximately 90% of its fatty acid content.
Limited high-quality clinical evidence exists, with most data from preclinical, traditional, or small case studies rather than large-scale RCTs or meta-analyses. One case study documented virechana (purgation therapy) with Eranda taila in a single rheumatoid arthritis patient showing symptomatic relief, though without controls or specified sample size. No specific PubMed PMIDs for RCTs were identified in the available sources.
Traditional Ayurvedic dosing includes seed oil at 3-5 drops orally for laxative effects, and powder at 1-3 g after seed purification. For medicinal castor oil, 1-5 mL is suggested as the lowest effective amount. No standardized extracts with specific ricinoleic acid concentrations were detailed in clinical studies. Consult a healthcare provider before starting any new supplement.
Ricinus communis seed oil (castor oil) is composed primarily of fatty acids: ricinoleic acid (85–95% of total fatty acids), a hydroxylated monounsaturated omega-9 fatty acid that is the principal bioactive lipid responsible for laxative and anti-inflammatory effects. Minor fatty acids include linoleic acid (4–5%), oleic acid (2–4%), stearic acid (1–2%), and palmitic acid (0.5–1%). The seed kernel contains approximately 45–50% fixed oil by weight, 18–20% crude protein (including toxic lectin ricin and allergen CB-1A — these are largely removed during cold-pressing or heat processing of commercial castor oil), and 2–3% ash. Carbohydrate content is approximately 5–10% in whole seeds. Seeds contain the alkaloid ricinine (0.1–0.3% dry weight) and the phytotoxin ricin (up to 1–5% of seed protein), both of which are absent or negligible in pharmaceutical-grade castor oil after processing. Leaves contain flavonoids (rutin, quercetin glycosides at approximately 0.5–1.2 mg/g dry weight), tannins (2–5% dry weight), alkaloids (ricinine), and terpenoids. Roots and leaves contain kaempferol and its derivatives. Bioavailability note: Ricinoleic acid is hydrolyzed in the small intestine by lipases and acts locally on intestinal mucosa via EP3 prostaglandin receptors; systemic absorption is limited. Ricin, if present in unprocessed seed material, is highly toxic (estimated lethal dose ~1–10 μg/kg body weight) and is not present in processed castor oil at therapeutic concentrations. Mineral content of seeds includes calcium (~266 mg/100g), magnesium (~385 mg/100g), phosphorus (~670 mg/100g), and potassium (~~780 mg/100g), though seeds are not consumed directly due to toxicity concerns.
Ricinoleic acid, comprising 85-90% of eranda's fatty acid content, binds to prostaglandin E receptors in the small intestine, stimulating adenylyl cyclase and increasing cyclic AMP levels. This triggers chloride and water secretion into the intestinal lumen while enhancing smooth muscle contractions. The anti-inflammatory effects may involve cyclooxygenase inhibition and reduced pro-inflammatory cytokine production.
Eranda is FDA-approved as an osmotic laxative based on established safety and efficacy data, though specific randomized controlled trials were not identified in available sources. One uncontrolled case study reported symptomatic improvement in a rheumatoid arthritis patient using eranda preparations. In vitro studies demonstrate antibacterial activity against various pathogens, but human clinical trials are lacking. The evidence base remains limited primarily to traditional use and preliminary laboratory research.
Eranda oil can cause severe abdominal cramping, nausea, and diarrhea, particularly at higher doses. It may reduce absorption of fat-soluble vitamins (A, D, E, K) and interact with anticoagulant medications by affecting vitamin K status. Eranda is contraindicated during pregnancy as ricinoleic acid can stimulate uterine contractions and potentially cause miscarriage. Individuals with intestinal obstruction, appendicitis, or inflammatory bowel conditions should avoid use.
